46-53 of 53
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
CME/CEDirected Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Lucio Manenti, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
CME/CEKALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Separating Fact from Fiction: The Realities of CKD-aP
CME/CESeparating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
Combining Biologics in a Young Patient with Atopic Dermatitis
CME/CECombining Biologics in a Young Patient with Atopic Dermatitis
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
Using a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis
CME/CEUsing a Biologic in a Patient with Atopic Dermatitis and HSV Keratitis
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
- advertisement
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
Advances in the Management of Moderate-to-Severe Atopic Dermatitis
CME/CEAdvances in the Management of Moderate-to-Severe Atopic Dermatitis
Peter A. Lio, MD
Eric Simpson, MD, MCR
Mark Boguniewicz, MD
